Elevated serum activin A and PD-L1 and survival in the CCTG MA.31 phase III trial (trastuzumab vs. lapatinib) in first-line HER2+ metastatic breast cancer.

Prashanth Reddy Moku,Lois E. Shepherd,Suhail M. Ali,Kim Leitzel,Wendy R. Parulekar,Liting Zhu,Shakeel Virk,Dora Nomikos,Samuel Aparicio,Karen A. Gelmon,Joseph J. Drabick,Leah Cream,Scott Halstead,Hyma Vani Polimera,Ashok Maddukuri,Aamnah Ali,Joyson Poulose,Howard Spiegel,Bingshu E. Chen,Allan Lipton

Elevated serum activin A and PD-L1 and survival in the CCTG MA.31 phase III trial (trastuzumab vs. lapatinib) in first-line HER2+ metastatic breast cancer.

2019

1031Background: In MA.31 the trastuzumab-taxane combination led to longer PFS than lapatinib-taxane in HER2+ metastatic breast cancer (MBC). In MA.31 we previously reported the prognostic/predictiv...

Keywords:

PD-L1
Trastuzumab
Oncology
Lapatinib
Pathology
Metastatic breast cancer
Internal medicine
Medicine
elevated serum
activin a
first line

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations